Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Voyager Therapeutics (Nasdaq: VYGR), a biotechnology company focused on neurogenetic medicines, has granted inducement awards to a new employee. The awards, approved by the Compensation Committee under Nasdaq Rule 5635(c)(4), include:
1. A non-qualified stock option for 40,000 shares of common stock, effective August 28, 2024, with a ten-year term and an exercise price of $6.49 per share. It vests over four years: 25% after one year, then 75% monthly over three years.
2. Restricted stock units for 20,000 shares, effective October 1, 2024, vesting annually in equal installments over three years.
Both awards are subject to continued employment and specific award agreements.
Voyager Therapeutics (Nasdaq: VYGR), una compagnia biotecnologica focalizzata su medicinali neurogenetici, ha concesso premi di assunzione a un nuovo dipendente. I premi, approvati dal Comitato di Compensazione ai sensi della Regola Nasdaq 5635(c)(4), comprendono:
1. Un'opzione su azioni non qualificate per 40.000 azioni di azioni ordinarie, efficace dal 28 agosto 2024, con un termine di dieci anni e un prezzo di esercizio di $6,49 per azione. Matura in quattro anni: il 25% dopo un anno, poi il 75% mensilmente per tre anni.
2. Unità di azioni restrittive per 20.000 azioni, efficace dal 1 ottobre 2024, con maturazione annuale in rate uguali per tre anni.
Entrambi i premi sono soggetti a occupazione continuativa e specifici accordi sui premi.
Voyager Therapeutics (Nasdaq: VYGR), una empresa biotecnológica centrada en medicamentos neurogenéticos, ha otorgado premios de incentivo a un nuevo empleado. Los premios, aprobados por el Comité de Compensación bajo la Regla Nasdaq 5635(c)(4), incluyen:
1. Una opción de acciones no calificadas por 40,000 acciones de acciones comunes, efectiva a partir del 28 de agosto de 2024, con un plazo de diez años y un precio de ejercicio de $6.49 por acción. Se consolida durante cuatro años: el 25% después de un año, luego el 75% mensualmente durante tres años.
2. Unidades de acciones restringidas por 20,000 acciones, efectivas a partir del 1 de octubre de 2024, que se consolidan anualmente en partes iguales durante tres años.
Ambos premios están sujetos a empleo continuado y a acuerdos específicos sobre los premios.
보이저 치료제(Voyager Therapeutics) (Nasdaq: VYGR), 신경유전학 의약품에 중점을 둔 생명공학 회사가 새로운 직원에게 인센티브 상을 수여했습니다. 해당 상은 Nasdaq 규칙 5635(c)(4)에 따라 보상 위원회 승인을 받았으며, 포함 내용은 다음과 같습니다:
1. 40,000주의 보통주에 대한 비자격 주식옵션으로, 2024년 8월 28일부터 발효되며, 10년 기간과 주당 $6.49의 행사 가격을 가집니다. 4년 동안 분할 행사되며, 1년 후 25%가 행사되고, 이후 3년 동안 월별로 75%가 행사됩니다.
2. 20,000주에 대한 제한된 주식 단위가 2024년 10월 1일부터 효력이 발생하며, 3년 동안 연간 동일한 비율로 행사됩니다.
두 가지 상 모두 계속 고용 상태와 특정 상에 대한 계약 조건을 충족해야 합니다.
Voyager Therapeutics (Nasdaq: VYGR), une entreprise biotechnologique spécialisée dans les médicaments neurogénétiques, a accordé des primes d'incitation à un nouvel employé. Les primes, approuvées par le Comité de Rémunération conformément à la Règle Nasdaq 5635(c)(4), comprennent :
1. Une option d'achat d'actions non qualifiée pour 40 000 actions ordinaires, prenant effet le 28 août 2024, avec une durée de dix ans et un prix d'exercice de 6,49 $ par action. Elle s'acquiert sur quatre ans : 25 % après un an, puis 75 % chaque mois pendant trois ans.
2. Des unités d'actions restreintes pour 20 000 actions, prenant effet le 1er octobre 2024, avec une acquisition annuelle en parts égales sur trois ans.
Les deux primes sont soumises à une poursuite d'emploi et à des accords spécifiques sur les primes.
Voyager Therapeutics (Nasdaq: VYGR), ein biotechnologisches Unternehmen, das sich auf neurogenetische Medikamente spezialisiert hat, hat Anreizpreise an einen neuen Mitarbeiter vergeben. Die Preise, die vom Vergütungsausschuss gemäß Nasdaq-Regel 5635(c)(4) genehmigt wurden, umfassen:
1. Eine nicht qualifizierte Aktienoption für 40.000 Aktien von Stammaktien, ab dem 28. August 2024 wirksam, mit einer Laufzeit von zehn Jahren und einem Ausübungspreis von $6,49 pro Aktie. Sie wird über vier Jahre verteilt: 25 % nach einem Jahr, dann 75 % monatlich über drei Jahre.
2. Eingeschränkte Aktieneinheiten für 20.000 Aktien, die ab dem 1. Oktober 2024 wirksam werden und über drei Jahre jährlich in gleichen Raten aufgeschlüsselt werden.
Beide Auszeichnungen unterliegen der fortdauernden Beschäftigung und spezifischen Auszeichnungsvereinbarungen.
- Voyager Therapeutics is attracting new talent with competitive equity compensation packages
- The company is complying with Nasdaq listing rules for inducement grants
- The equity grants may lead to potential dilution for existing shareholders
LEXINGTON, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, has entered into an employment agreement with a newly hired employee that, among other things, provides for the grant to such employee of a non-qualified stock option and restricted stock units as an inducement material to such employee’s entering into employment with Voyager. The inducement awards were approved by the Compensation Committee of Voyager’s Board of Directors in accordance with Nasdaq Stock Market Listing Rule 5635(c)(4). The option award became effective on August 28, 2024, and the restricted stock unit award is scheduled to become effective on October 1, 2024.
The stock option award provides for the purchase of an aggregate of 40,000 shares of Voyager’s common stock, and the restricted stock unit award will represent 20,000 shares of Voyager’s common stock. The stock option has a ten-year term and an exercise price of
About Voyager Therapeutics
Voyager Therapeutics, Inc. (Nasdaq: VYGR) is a biotechnology company dedicated to leveraging the power of human genetics to modify the course of – and ultimately cure – neurological diseases. Our pipeline includes programs for Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple other diseases of the central nervous system. Many of our programs are derived from our TRACER™ AAV capsid discovery platform, which we have used to generate novel capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Some of our programs are wholly owned, and some are advancing with partners including Alexion, AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc.; and Sangamo Therapeutics, Inc. For more information, visit www.voyagertherapeutics.com.
Voyager Therapeutics® is a registered trademark, and TRACER™ is a trademark, of Voyager Therapeutics, Inc.
Contacts
Trista Morrison, NACD.DC, tmorrison@vygr.com
Investors: Adam Bero, Ph.D., abero@kendallir.com
Media: Brooke Shenkin, brooke@scientpr.com
FAQ
What type of inducement grants did Voyager Therapeutics (VYGR) announce on August 29, 2024?
What is the exercise price and vesting schedule for the stock option grant by Voyager Therapeutics (VYGR)?
When do the restricted stock units granted by Voyager Therapeutics (VYGR) become effective and how do they vest?
Under which Nasdaq rule did Voyager Therapeutics (VYGR) approve these inducement grants?
